About Par Formulations Private Limited
Data last updated:
Par Formulations Private Limited is a private limited company based in Chennai, Tamil Nadu, India, a subsidiary of Par Pharmaceuticals Inc.. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 September 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U33111TN1982PTC009602. Its GSTIN is 33AAACC2463N1ZP (Tamil Nadu). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹2.2 Cr and a paid-up capital of ₹2.14 Cr. It was formerly known as Novel Therapeutics Private Limited and Edict Pharmaceuticals Private Limited. It is led by directors Chitti Babu Sampath Kumar (Whole-Time Director) and Anand Amrit Raj.
Its last annual general meeting (AGM) was held on 26 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 9/215 Pudupakkam – Vandalur Main Road Pudupakkam Kelambakkam, Chennai, Tamil Nadu, India – 603103.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,462.09 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net profit of ₹28.41 Cr (net margin 1.9%) and EBITDA of ₹252.79 Cr (EBITDA margin 17.3%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 19% over five years.
The company has about 1,304 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 2 brands: Endo International and Par Pharmaceutical Companies. As per MCA filings, the company has open charges of ₹17.13 Lakh and satisfied charges of ₹62.37 Cr on record. Court records list 17 cases involving the company, including 15 filed by the company and 2 filed against it; 7 cases are pending. The company has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Indoco Remedies Limited with revenue of ₹1,670.37 Cr. The company has 7 MSME Form 1 returns on record between 2019 and 2024, listing 76 overdue payments to 26 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website parpharm.com.
Name History of Par Formulations Private Limited
Par Formulations has undergone 4 name changes throughout its history. The current legal name is Par Formulations Private Limited.
| Company Name | Status |
|---|---|
| Par Formulations Private Limited | Current |
| Novel Therapeutics Private Limited | Previous |
| Edict Pharmaceuticals Private Limited | Previous |
| Chk Electroniks Private Limited | Previous |
| Ch Krishnan And Associates Private Limited | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address9/215 Pudupakkam – Vandalur Main Road Pudupakkam Kelambakkam, Chennai, Tamil Nadu, India – 603103
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Par Formulations Private Limited
Par Formulations operates two associated brands: Endo International and Par Pharmaceutical Companies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines | endo.com | |
| Pharmaceutical products are developed for endocrinology, orthopedics, and urology. | parpharm.com |
Business Activity of Par Formulations Private Limited
The main business activities of Par Formulations are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and scientific research and development. 2 activity segments are registered with the MCA.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Par Formulations Private Limited FY 2024 filings available
Par Formulations Private Limited reported revenue of ₹1,462.09 Cr (up 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Par Formulations Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 19% over five years, including 5% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Par Formulations Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹252.79 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹28.41 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Par Formulations Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.3% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Par Formulations are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Par Formulations Private Limited
Par Formulations has 2 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chitti Babu Sampath Kumar | Whole-Time Director | 28 Jun 2017 | 9 Years 3 Months | Current |
| Anand Amrit Raj | Director | 27 May 2022 | 4 Years 4 Months | Current |
Peer Comparison of Par Formulations Private Limited
Par Formulations Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Indoco Remedies Limited Listed | ₹1,670.37 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | Mumbai, Maharashtra, India |
| Pure and Cure Healthcare Private Limited | ₹1,647.61 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Saraswati Vihar, Delhi, India |
| Annora Pharma Private Limited | ₹1,493.96 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Gummadidala Mandal, Telangana, India |
| Synthimed Labs Private Limited | ₹1,478.44 Cr (FY 2025) | •••• | •••• | 25706.0% | •••• | Chandigarh, India |
| Onesource Specialty Pharma Limited | ₹1,462.33 Cr (FY 2025) | •••• | •••• | 730.0% | •••• | Thane, Maharashtra, India |
| Par Formulations Private Limited this company | ₹1,462.09 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Chennai, Tamil Nadu, India |
| Encube Ethicals Private Limited | ₹1,369 Cr (FY 2025) | •••• | •••• | 25.0% | •••• | Mumbai, Maharashtra, India |
| Shasun Pharmaceuticals Limited | ₹1,328.86 Cr (FY 2015) | •••• | •••• | 8.0% | •••• | Chennai, Tamil Nadu, India |
| Sentiss Pharma Private Limited | ₹1,262.74 Cr (FY 2025) | •••• | •••• | 43.0% | •••• | New Delhi, Delhi, India |
| Elder Pharmaceuticals Limited | ₹1,259.31 Cr (FY 2013) | •••• | •••• | 25.0% | •••• | Mumbai, Maharashtra, India |
| Innova Captab Limited | ₹1,255.72 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Thane, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Par Formulations by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Par Formulations Private Limited
Par Formulations Private Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Price Waterhouse & Co Chartered Accountants LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Par Formulations Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Par Formulations Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Aug 2022 | Others | ₹12.13 Lakh | Open |
| 08 Aug 2022 | Others | ₹5 Lakh | Open |
| 08 Aug 2022 | Others | ₹27.06 Cr | Satisfied |
| 04 Feb 2010 | State Bank of India | ₹18 Cr | Satisfied |
| 06 Mar 2008 | State Bank of India | ₹15 Cr | Satisfied |
Total charge records: 10 View all charges
Deals & Funding of Par Formulations Private Limited
Par Formulations Private Limited has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023.
Deals on record (5 of 16)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: Endo India Holdings LLC Seller: Par Pharmaceuticals Inc, Par Llc |
| Feb 2012 | Secondary share transfer | Undisclosed | Buyer: Par Llc, Par Pharmaceuticals Inc Seller: Clan Laboratories Private Limited , Thretha Investments and Portfolio Services Private Limited , 2 individuals |
| Oct 2009 | Secondary share transfer | Undisclosed | Buyer: Clan Laboratories Private Limited Seller: Ordain Health Care Private Limited |
| Aug 2009 | Funding round | ₹79.3 Lakh | Investors: Thretha Investments and Portfolio Services Private Limited , an individual |
| Mar 2009 | Secondary share transfer | Undisclosed | Buyer: Clan Laboratories Private Limited Seller: an individual |
Full deal history
All 16 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Par Formulations Private Limited
Par Formulations Private Limited has 17 court cases on record: 15 filed by Par Formulations, 2 filed against it. 7 cases are pending and 10 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 1 | 3 |
| NCLAT | 5 | 0 | 4 |
| District courts | 2 | 1 | 0 |
Cases on record (5 of 17)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, New Delhi | Interim or miscellaneous application | Filed by the company against Print House (India) Private Limited and 2 others | Pending |
| NCLAT, New Delhi | Insolvency matter | Filed by the company against Print House (India) Private Limited and 2 others | Disposed |
| Madras High Court | Interim or miscellaneous application | Filed against the company by Additional Commissioner of CGST and Central Excise | Pending |
| Madras High Court | Interim or miscellaneous application | Filed by the company against Additional Commissioner of CGST and Central Excise | Pending |
| Madras High Court | Writ petition | Filed by the company against Additional Commissioner of CGST and Central Excise | Pending |
Full case history
All 17 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Par Formulations Private Limited
Par Formulations Private Limited has 7 MSME Form 1 returns on record between 2019 and 2024, listing 76 overdue payments to 26 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 26)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| Anant Pharmaceuticals Private Limited | •••• | •••• | •••• |
| Human Lifescience | •••• | •••• | •••• |
| Chromatography World | •••• | •••• | •••• |
| Chempura Enterprises | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 7 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Par Formulations Private Limited
Par Formulations Private Limited has a workforce of 1,304 employees as of Apr 05, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Par Formulations Private Limited
Par Formulations has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Par Active Technologies Private Limited | U24232TN2013PTC093471 | Locked |
| Par Biosciences Private Limited | U24233TN2012PTC086326 | Locked |
Showing major subsidiaries. Total: 2.
Recent Activity on Par Formulations Private Limited
Par Formulations Private Limited has 26 board changes on record since 2007: 4 appointments and 22 cessations. The latest: Nazneen Nasir Khan was appointed as Company Secretary on 16 Jul 2025.
38 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Par Formulations Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Par Formulations Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Par Formulations Private Limited
Par Formulations has 3 GST registrations: 3 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACC2463N1ZP | Tamil Nadu | Active | 01 Jul 2017 |
| 27AAACC2463N1ZI | Maharashtra | Active | 15 Aug 2017 |
| 23AAACC2463N1ZQ | Madhya Pradesh | Active | 13 Apr 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Par Formulations Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Par Formulations Private Limited
Par Formulations is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 September 1982 (44+ years old) and is registered under CIN U33111TN1982PTC009602.
Par Formulations reported revenue of ₹1,462.09 Cr for FY 2025 (up 5% YoY).
Par Formulations has 2 current directors:
- Chitti Babu Sampath Kumar - Whole-Time Director
- Anand Amrit Raj - Director
Par Formulations reported a net profit of ₹28.41 Cr (net margin 1.9%) and EBITDA of ₹252.79 Cr (EBITDA margin 17.3%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Par Formulations is 13% over three years and 19% over five years. In the latest year (FY 2025) revenue rose 5%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Par Formulations is 33AAACC2463N1ZP, registered in Tamil Nadu. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 27AAACC2463N1ZI (Maharashtra), 23AAACC2463N1ZQ (Madhya Pradesh).
The CIN (Corporate Identification Number) of Par Formulations is U33111TN1982PTC009602. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Par Formulations has 17 court cases on record: 15 filed by the company and 2 filed against it. 7 are pending. Most are in the high courts.
Par Formulations was incorporated on 22 September 1982, making it 44+ years old. It is registered with the Registrar of Companies, Chennai.
Par Formulations has 16 deals on record (8 funding rounds, 7 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹187.08 Cr; the latest was in March 2023.
The peers of Par Formulations by revenue are Indoco Remedies Limited, Pure and Cure Healthcare Private Limited, Annora Pharma Private Limited, Synthimed Labs Private Limited, Onesource Specialty Pharma Limited and 5 more, all in the Pharma industry (Formulations).
Nazneen Nasir Khan was appointed as Company Secretary on 16 Jul 2025. Anand Amrit Raj ceased to be Additional Director on 30 Sep 2022. Anand Amrit Raj was appointed as Director on 27 May 2022. Par Formulations has 26 board changes on record in total.